Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Ty21a immunotherapy of non-muscle-invasive bladder cancer

Funder: Swiss National Science Foundation

Funding period
CHF 429 K
USD 437 K
Funding amount
Abstract
Ty21a immunotherapy of non-muscle-invasive bladder cancer1. SUMMARY Bladder cancer is the fourth and eighth most common malignancy among men and women, respectively. Seventy percent of tumors present as non muscle-invasive bladder cancer (NMIBC) at initial diagnosis with variable risk of recurrence and progression to invasive disease, thus requiring long-term surveillance. Intravesical BCG immunotherapy can reduce recurrence/progression of NMIBC, although significant adverse events and treatment failure argue for alternative options. During the ongoing granting period we have examined how another live vaccine, Vivotif®, consisting of the highly attenuated Salmonella enterica serovar Typhi strain Ty21a, used since more than 30 years against typhoid fever, may be safely used intravesically to improve bladder-tumor treatment. Our prepreclinical data demonstrate that Ty21a is more efficient than BCG at regressing established bladder tumor in the MB49-orthotopic murine model of NMBIC. This was confirmed by the ability of Ty21a to kill human tumor-cells in vitro and induce, in a novel human 3D-bladder-tissue ex-vivo assay, specific cytokines/chemokines/growth factors associated with efficient bladder-treatment. Our data confirmed a high safety, with no Ty21a bacteria persisting in mouse and human bladder tissues in contrast to BCG. Altogether, these data are of good premise for the use of the typhoid vaccine for intravesical immunotherapy of NMIBC patients.The purpose of this grant proposal is to achieve a two-steps Phase I trial with Ty21a, in order to obtain safety and immunogenicity data in patients, together with hints towards efficacy.
Similar projects All >
Sorted by: Start Date
Project list item
CD40 agonism for the treatment of bladder cancer

National Cancer Institute to CHRISTOPHER STUART GARRIS

USD 64,554
2020 - 2023
Project list item
Roles of epigenetic regulators in bladder cancer progression

University of California - Cancer Research Coordinating Committee to Zhu Wang

USD 74,960
2020 - 2020
Project list item
Engineering Smart Solutions for Disorders of the Bladder Urothelium

Engineering and Physical Sciences Research Council

 
2019 - 2023
Project list item
Geriatric Conditions and Treatment Burden in Older Adults with Non-Muscle-Invasive Bladder Cancer and Their Caregivers

National Institute on Aging to TULLIKA GARG

USD 135,849
2019 - 2021
Project list item
Developing a SMART scaffold for bladder augmentation

National Institute of Biomedical Imaging and Bioengineering to GUILLERMO ANTONIO AMEER, ARUN SHARMA, JOHN ROGERS

USD 709,004
2019 - 2023

System

Categories
  • FOR (ANZSRC)

    1103 Clinical Sciences

  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Biotechnology

  • RCDC

    Cancer

  • RCDC

    Clinical Research

  • RCDC

    Immunization

  • RCDC

    Rare Diseases

  • RCDC

    Urologic Diseases

  • RCDC

    Vaccine Related

  • HRCS HC

    Cancer

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Clinical Medicine and Science